|
|
|
02.06.26 - 14:33
|
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the trading resumption of its ordinary shares on the regulated market of Euronext in Paris as from 3:30 p.m. CEST....
|
|
|
|
|
|
|
02.06.26 - 14:21
|
XETR: FR0013233012: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME Waehrung/Currency ISIN BIS/UNTIL
INVENTIVA S.A.(PROM.)-,01 EUR FR0013233012 BAW/UFN...
|
|
|
02.06.26 - 14:21
|
XFRA: 6IV: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
INVENTIVA S.A.(PROM.)-,01 6IV FR0013233012 BAW/UFN...
|
|
|
02.06.26 - 07:33
|
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), June 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announces that the listing of its ordinary shares on the regulated market of Euronext Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST....
|
|
|
|
|
26.05.26 - 22:03
|
Inventiva Reports 2026 First Quarter Financial Information¹ (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), May 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first quarter of 2026, including its cash, cash equivalents and revenues....
|
|
|
21.05.26 - 22:03
|
Inventiva to Present at 2026 Jefferies Global Healthcare Conference (GlobeNewswire EN)
|
|
|
Daix (France), New York (United States), May 21, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain will present at at the upcoming 2026 Jefferies Global Healthcare Conference. The conference is being held June 2-4, 2026, in New York City....
|
|
|
13.05.26 - 08:33
|
Inventiva to Present Abstracts at the EASL Congress 2026 (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the presentation of two abstracts at the upcoming annual congress of the European Association for the Study of the Liver, EASL Congress 2026, to be held from May 27 to 30, 2026 in Barcelona....
|
|
|
|
|
|
|
17.04.26 - 17:12
|
XETR: Deletion of Instruments from XETRA - 17.04.2026 -1- (XETRA)
|
|
|
The following instruments on XETRA do have their last trading day on 17.04.2026.
Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 17.04.2026.
ISIN Name
US0028962076 Abercrombie & Fitch Co.
US0162551016 Align Technology Inc.
US02043Q1076 Alnylam Pharmaceuticals Inc.
US0255371017 American Electric Power Co. Inc.
US0311001004 AMETEK Inc.
US0530151036 Automatic Data Processing Inc.
GB00BPQY8M80 Aviva PLC
IE00BD1RP616 Bank of Ireland Group PLC
US14448C1045 Carrier Global Corp.
US8085131055 Charles Schwab Corp.
US16119P1084 Charter Communications Inc. [Del.]
US1713401024 Church & Dwight Co. Inc.
US1255231003 Cigna Group, The
US1729081059 Cintas Corp.
US12572Q1058 CME Group Inc.
US1924461023 Cognizant Technology Solutions Corp.
US2091151041 Consolidated Edison Inc.
US22052L1044 Corteva Inc.
US1264081035 CSX Corp.
US2310211063 Cummins Inc.
US2435371073 Deckers Outdoor Corp.
DK0060738599 Demant AS
US2533931026 Dics Sporting Goods Inc.
US2566771059 Dollar General Co...
|
|
|
08.04.26 - 22:03
|
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it had filed its 2025 Universal Registration Document for the year ended December 31, 2025, including the management report and the annual financial report, with the French Autorité des Marchés Financiers (“AMF”) and its 2025 Annual Report on Form 20-F for the year ended December 31, 2025 with the U.S. Securities and Exchange Commission (“SEC”)....
|
|
|
|
|
30.03.26 - 22:12
|
Inventiva reports 2025 full year results and provides a business update (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), March 30, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial results for the full year ended December 31, 2025 and also provided a business update....
|
|
|
23.03.26 - 22:03
|
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results (GlobeNewswire EN)
|
|
|
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that it will release its 2025 full-year financial results on Monday, March 30, 2026, after market close in the United States....
|
|
|
|
|
17.02.26 - 08:33
|
Inventiva reports preliminary 2025¹ fiscal year financial results (GlobeNewswire EN)
|
|
|
Daix (France), New York City (New York, United States), February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its certain preliminary unaudited financial results for the full year ending December 31, 2025, including cash, cash equivalents, and revenues....
|
|
|
04.02.26 - 22:03
|
Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire EN)
|
|
|
Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
